Anika and Galderma terminate Elevess-related agreements

Anika has now reacquired the worldwide rights to the future development and marketing of Elevess, including ownership of the Elevess trademark, and all related packaging, marketing and promotional materials, as well as the clinical studies, marketing research and training materials developed by Galderma Pharma and Galderma.

According to Anika, Elevess is the first injectable soft-tissue filler for facial wrinkles, scar remediation and lip augmentation.

Gregory Fulton, vice president of marketing, aesthetics and ophthalmics, Anika, said: “We have begun moving forward in the search for a new partner for Elevess. There has been considerable interest expressed already by new potential partners, and we are actively pursuing these opportunities. In addition, we are continuing with pre-launch activities, which include reaching out to key opinion leaders. We plan to launch Elevess in the first half of next year and are confident that we will execute on our strategy to make dermal fillers an important franchise for the company.”